Ciprofloxacin-dexamethasone otic — Membership Pricing

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Acute Otitis Media/Externa (Ear Infection)

• Amoxicillin

What Ciprofloxacin-dexamethasone otic is approved for (FDA label)

Ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the specific conditions listed below: Acute Otitis Media (AOM) in pediatric patients (age 6 months and older) with tympanostomy tubes due to Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis , and Pseudomonas aeruginosa.

Source: Read the full FDA label on DailyMed. Label effective date: July 13, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Ciprofloxacin-dexamethasone otic (FDA label)

Otic Suspension: Each mL of ciprofloxacin and dexamethasone otic suspension USP, contains ciprofloxacin hydrochloride USP 0.3% (equivalent to 3 mg ciprofloxacin base) and dexamethasone USP, 0.1% equivalent to 1 mg dexamethasone. Otic Suspension: Each mL of ciprofloxacin and dexamethasone otic suspension contains ciprofloxacin hydrochloride 0.3% (equivalent to 3 mg ciprofloxacin base) and dexamethasone 0.1% (equivalent to 1 mg dexamethasone). (3)

Source: FDA prescribing information (DailyMed). Set ID: 780a5554-54ef-4294-b681-8c5300b028b6. SPL document ID: 567b0c1f-2a68-ea09-e063-6394a90a4a9d. Label effective date: July 13, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Ciprofloxacin-dexamethasone otic (FDA label)

The following serious adverse reactions are described elsewhere in the labeling: • Hypersensitivity Reactions [see Warnings and Precautions ( 5.1 )] • Potential for Microbial Overgrowth with Prolonged Use [see Warnings and Precautions ( 5.2)] Most common adverse reactions were ear discomfort (3%), ear pain (2.3%), and ear pruritus (1.5%). (6) To report SUSPECTED ADVERSE REACTIONS, contact Dr. REDDY’S LABORATORIES Inc., at 1-888-375-3784 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to the rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 780a5554-54ef-4294-b681-8c5300b028b6. SPL document ID: 567b0c1f-2a68-ea09-e063-6394a90a4a9d. Label effective date: July 13, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Ciprofloxacin-dexamethasone otic (FDA label)

Ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension is contraindicated in patients with a history of hypersensitivity to ciprofloxacin, to other quinolones, or to any of the components in this medication. Use of this product is contraindicated in viral infections of the external canal, including herpes simplex infections and fungal otic infections. • Ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension is contraindicated in patients with a history of hypersensitivity to ciprofloxacin, to other quinolones, or to any of the components in this medication. ( 4 ) • Use of this product is contraindicated in viral infections of the external canal, including herpes simplex infections and fungal otic infections. (4)

Source: FDA prescribing information (DailyMed). Set ID: 780a5554-54ef-4294-b681-8c5300b028b6. SPL document ID: 567b0c1f-2a68-ea09-e063-6394a90a4a9d. Label effective date: July 13, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Ciprofloxacin-dexamethasone otic (FDA label)

• Hypersensitivity and anaphylaxis have been reported with systemic use of quinolones. Discontinue use if this occurs with use of ciprofloxacin 0.3% and dexamethasone 0.1%otic suspension. ( 5.1) • Prolonged use may result in overgrowth of non-susceptible bacteria and fungi. ( 5.2) 5.1 Hypersensitivity Reactions Ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension should be discontinued at the first appearance of a skin rash or any other sign of hypersensitivity. Serious and occasionally fatal hypersensitivity (anaphylactic) reactions, some following the first dose, have been reported in patients receiving systemic quinolones. Some reactions were accompanied by cardiovascular collapse, loss of consciousness, angioedema (including laryngeal, pharyngeal, or facial edema), airway obstruction, dyspnea, urticaria, and itching. 5.2 Potential for Microbial Overgrowth with Prolonged Use Prolonged use of ciprofloxacin 0.3% and dexamethasone 0.1%otic suspension may result in overgrowth of non-susceptible, bacteria and fungi.

Source: FDA prescribing information (DailyMed). Set ID: 780a5554-54ef-4294-b681-8c5300b028b6. SPL document ID: 567b0c1f-2a68-ea09-e063-6394a90a4a9d. Label effective date: July 13, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.